Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review

被引：5

作者：

Gauthe, Mathieu ^{[1
]}

Sargos, Paul ^{[2
]}

Barret, Eric ^{[3
]}

Fromont-Hankard, Gaelle ^{[4
]}

Beauval, Jean-Baptiste ^{[5
]}

Brureau, Laurent ^{[6
]}

Crehange, Gilles ^{[7
]}

Renard-Penna, Raphaele ^{[8
]}

Dariane, Charles ^{[9
]}

Fiard, Gaelle ^{[10
]}

Mathieu, Romain ^{[11
]}

Roubaud, Guilhem ^{[12
]}

Ruffion, Alain ^{[13
]}

Roupret, Morgan ^{[14
]}

Ploussard, Guillaume ^{[5
,15
]}

机构：

[1] Scintep, Dept Nucl Med, F-38000 Grenoble, France

[2] Inst Bergonie, Dept Radiotherapy, F-33000 Bordeaux, France

[3] Inst Mutualiste Montsouris, Dept Urol, F-75014 Paris, France

[4] CHRU Tours, Dept Pathol, F-37000 Tours, France

[5] La Croix Sud Hosp, Dept Urol, F-31445 Quint Fonsegrives, France

[6] Univ Antilles, CHU Pointe a Pitre, Irset Inst Rech Sante Environm & Travail, Dept Urol,INSERM,EHESP,UMR S 1085, F-97110 Pointe A Pitre, Guadeloupe, France

[7] Curie Inst, Dept Radiat Oncol, F-75005 Paris, France

[8] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, Radiol, F-75013 Paris, France

[9] Paris Paris Univ, Hop Europeen Georges Pompidou, AP HP, Dept Urol,INSERM,INEM,Necker,U1151, F-75015 Paris, France

[10] Univ Grenoble Alpes, Grenoble Alpes Univ Hosp, CNRS, Dept Urol,Grenoble INP,TIMC,IMAG, F-38000 Grenoble, France

[11] CHU Rennes, Dept Urol, F-35000 Rennes, France

[12] Inst Bergonie, Dept Med Oncol, F-33000 Bordeaux, France

[13] Univ Lyon 1, Hosp Civils Lyon, Equipe 2 Ctr Innovat Cancerol Lyon EA 3738 CICLY, Ctr Hosp Lyon Sud,Fac Med Lyon Sud,Serv Urol, F-69000 Lyon, France

[14] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, GRC 5 Predict Oncouro,Urol, F-75013 Paris, France

[15] Inst Univ Canc Oncopole, F-31000 Toulouse, France

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 21期

关键词：

nuclear medicine; therapeutics; molecular imaging; PEPTIDE RECEPTOR-ANTAGONIST; GLYCOLYTIC ACTIVITY; MEMBRANE ANTIGEN; BONE METASTASES; IN-VIVO; PET; EXPRESSION; BOMBESIN; DOSIMETRY; RECURRENT;

D O I：

10.3390/jcm10214909

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans. Methods: We performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms ( "prostate cancer ", "prostatic neoplasms ") and ( "radioligand ", "radiotracer "). Included articles were clinical studies. The results were synthetized by the target type. Results: We included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) (n = 23), androgen receptor (n = 11), somatostatin receptors (n = 6), urokinase plasminogen activator surface receptor (n = 4), fibroblast activation protein (n = 2 studies) and integrin receptors (n = 1). GRPRs, the most studied target, has a lower expression in high-grade PCa, CRPC and bone metastases. Its use might be of higher interest in treating earlier stages of PCa or low-grade PCa. Radiolabeled fibroblast activation protein inhibitors were the most recent and promising molecules, but specific studies reporting their interest in PCa are needed. Conclusion: Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted.

引用

页数：12

共 71 条

[1] PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model [J].